SMT201400160B - Nuove composizioni per il trattamento di cmt e malattie correlate - Google Patents

Nuove composizioni per il trattamento di cmt e malattie correlate

Info

Publication number
SMT201400160B
SMT201400160B SM201400160T SM201400160T SMT201400160B SM T201400160 B SMT201400160 B SM T201400160B SM 201400160 T SM201400160 T SM 201400160T SM 201400160 T SM201400160 T SM 201400160T SM T201400160 B SMT201400160 B SM T201400160B
Authority
SM
San Marino
Prior art keywords
cmt
treatment
related diseases
new compositions
compositions
Prior art date
Application number
SM201400160T
Other languages
English (en)
Italian (it)
Inventor
Serguei Nabirochkin
Daniel Cohen
Ilya Chumakov
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SMT201400160B publication Critical patent/SMT201400160B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201400160T 2009-06-02 2014-10-30 Nuove composizioni per il trattamento di cmt e malattie correlate SMT201400160B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305506A EP2263665A1 (de) 2009-06-02 2009-06-02 Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
EP10724399.0A EP2437742B1 (de) 2009-06-02 2010-05-28 Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
PCT/EP2010/057438 WO2010139627A1 (en) 2009-06-02 2010-05-28 New compositions for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
SMT201400160B true SMT201400160B (it) 2015-01-15

Family

ID=41168603

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400160T SMT201400160B (it) 2009-06-02 2014-10-30 Nuove composizioni per il trattamento di cmt e malattie correlate

Country Status (26)

Country Link
US (4) US20120088744A1 (de)
EP (4) EP2263665A1 (de)
JP (1) JP5875191B2 (de)
KR (1) KR101740336B1 (de)
CN (2) CN104688737B (de)
AR (1) AR077540A1 (de)
AU (1) AU2010255802B2 (de)
BR (1) BRPI1013302B1 (de)
CA (1) CA2763495C (de)
CY (1) CY1115736T1 (de)
DK (1) DK2437742T3 (de)
EA (1) EA024523B1 (de)
ES (2) ES2523268T3 (de)
HK (2) HK1206590A1 (de)
HR (1) HRP20141009T1 (de)
IL (1) IL216621A (de)
MX (1) MX345287B (de)
NZ (1) NZ596656A (de)
PL (1) PL2437742T3 (de)
PT (1) PT2437742E (de)
SG (1) SG176275A1 (de)
SI (1) SI2437742T1 (de)
SM (1) SMT201400160B (de)
UA (1) UA110013C2 (de)
WO (1) WO2010139627A1 (de)
ZA (1) ZA201109423B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
EP2135607A1 (de) 2008-06-18 2009-12-23 Pharnext Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen
EP2263665A1 (de) * 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) * 2011-03-01 2018-01-16 Pharnext Compositions for treating neurological disorders
SI2796132T1 (sl) 2011-03-01 2018-09-28 Pharnext Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
FR2987271B1 (fr) * 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
WO2014163380A1 (ko) * 2013-04-02 2014-10-09 사회복지법인 삼성생명공익재단 샤르코-마리-투스 질환 치료제의 스크리닝 방법 및 이에 이용되는 자가분화운동신경세포
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
RU2686110C1 (ru) 2013-12-13 2019-04-24 Пьер Фабр Медикамент Производное хромона в качестве антагониста дофаминового рецептора d3 для применения при лечении расстройства аутистического спектра
EP3104850A1 (de) 2014-02-11 2016-12-21 Pharnext Kombination aus baclofen, acamprosat und mittelkettigen triglyceriden zur behandlung neurologischer erkrankungen
EA201691703A1 (ru) * 2014-02-24 2017-04-28 Фарнекст Новые композиции для лечения механических повреждений нервов
WO2016191241A1 (en) * 2015-05-27 2016-12-01 Mmc & Company Llc Dual target mitochondrial impinging pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
CN111658643B (zh) * 2020-07-31 2021-12-07 西安交通大学医学院第一附属医院 雷帕霉素在难治性Graves病中的制药应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
AU9187598A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Oral preparation
WO2000020024A2 (en) 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) * 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
CN1652752A (zh) 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20050038062A1 (en) 2003-04-14 2005-02-17 Burns Lindsay H. Methods and materials for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
MXPA06003392A (es) 2003-09-25 2006-06-08 Euro Celtique Sa Combinacion farmaceutica de hidrocodona y naltrexona.
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
EP2026813A2 (de) 2006-05-09 2009-02-25 Braincells, Inc. 5-ht-rezeptor-vermittelte neurogenese
EP2117517B1 (de) 2007-01-11 2011-06-01 XenoPort, Inc. Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
EP2065821A1 (de) 2007-11-30 2009-06-03 Pharnext Neue Krankheitsbehandlung durch Vorhersage von Arzneimittelverbindungen
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
EP2135607A1 (de) * 2008-06-18 2009-12-23 Pharnext Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (de) 2009-11-03 2011-05-18 Pharnext Neue therapeutische Ansätze zur Behandlung von Alzheimer-Krankheit
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
SI2796132T1 (sl) 2011-03-01 2018-09-28 Pharnext Terapija nevroloških motenj, ki temelji na baklofenu in akamprozatu
CA2913331C (en) 2013-06-05 2021-08-24 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
AR077540A1 (es) 2011-09-07
JP5875191B2 (ja) 2016-03-02
CA2763495A1 (en) 2010-12-09
CN102458387A (zh) 2012-05-16
CN102458387B (zh) 2015-01-28
PL2437742T3 (pl) 2015-03-31
EA024523B1 (ru) 2016-09-30
US11672796B2 (en) 2023-06-13
MX345287B (es) 2017-01-24
HRP20141009T1 (hr) 2015-01-30
JP2012528818A (ja) 2012-11-15
EP2823817A1 (de) 2015-01-14
ES2523268T3 (es) 2014-11-24
MX2011012817A (es) 2011-12-16
PT2437742E (pt) 2014-11-04
AU2010255802A1 (en) 2011-12-22
IL216621A (en) 2016-05-31
KR101740336B1 (ko) 2017-06-08
HK1206590A1 (en) 2016-01-15
CA2763495C (en) 2018-06-26
EP3246025A1 (de) 2017-11-22
ZA201109423B (en) 2012-09-26
NZ596656A (en) 2013-08-30
EA201101686A1 (ru) 2012-06-29
EP2437742A1 (de) 2012-04-11
ES2641191T3 (es) 2017-11-08
CN104688737A (zh) 2015-06-10
CY1115736T1 (el) 2017-01-25
UA110013C2 (uk) 2015-11-10
WO2010139627A1 (en) 2010-12-09
HK1170150A1 (en) 2013-02-22
US9427436B1 (en) 2016-08-30
EP2437742B1 (de) 2014-08-06
EP2823817B1 (de) 2017-06-21
US20210322402A1 (en) 2021-10-21
DK2437742T3 (da) 2014-11-03
CN104688737B (zh) 2019-11-08
KR20120027353A (ko) 2012-03-21
BRPI1013302A2 (pt) 2018-01-09
BRPI1013302B1 (pt) 2022-07-12
AU2010255802B2 (en) 2014-08-14
US20180250290A1 (en) 2018-09-06
SG176275A1 (en) 2012-01-30
IL216621A0 (en) 2012-02-29
EP2263665A1 (de) 2010-12-22
SI2437742T1 (sl) 2015-02-27
US10905686B2 (en) 2021-02-02
US20160263104A1 (en) 2016-09-15
US20120088744A1 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
SMT201400160B (it) Nuove composizioni per il trattamento di cmt e malattie correlate
SMT201600254B (it) Procedimento per la preparazione di idromagnesite
BRPI1011587A2 (pt) compostos e composições terapèuticas
SMT201400169B (it) Nuovo composto utile per il trattamento di malattie degenerative e infiammantorie
HK1166305A1 (zh) 用於治療炎症的組合物及方法
SMT201400165B (it) Composizioni e metodi per il trattamento di sclerosi multipla
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
SMT201600332B (it) Composizioni e metodi per l’aumento dell’attivitàtelomerasica
IT1403587B1 (it) Composizione per il trattamento di disordini metabolici
EP2424512A4 (de) Verfahren und zusammensetzungen zur verbesserung des gesundheitszustandes von tieren
EP2416803A4 (de) Neue verfahren zur behandlung von entzündungserkrankungen
HU0900231D0 (en) Compositions for the treatment of allergic disorders
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
IL223385B (en) Treatment of inflammatory disorders
EP2600864A4 (de) Zusammensetzungen und verfahren zur behandlung von entzündungskrankheiten
IT1403064B1 (it) Composizione di sostanze per il trattamento di pazienti con ipercolesterolemia e patologie collegate
IT1395276B1 (it) Agenti coadiuvanti di vulcanizzazione
IT1398273B1 (it) Procedimento per la preparazione di 14-bromo daunomicina
IT1403250B1 (it) Macroapparato per la produzione e il trattamento di gas
GB0819446D0 (en) Treatment of inflammatory disorders
GB0921929D0 (en) Compositions and methods for the treatment of influenza
UA20566S (uk) Блок крісел
TH104676B (th) ชุดติดตั้งอุปกรณ์ชำระล้างสำเร็จรูป
BRPI1015355A2 (pt) composições e métodos de incorporação de fotocatalisadores
TH111314B (th) อุปกรณ์ทางทันตกรรม